Ferric Carboxymaltose Injection Suppliers & Bulk Manufacturers
Available Forms: Injectable
Available Strengths: 50 mg /mL vial
Reference Brands: Injectafer (US) and Ferinject (EU)
Category:
Nephrology
Ferric Carboxymaltose is a fast-acting intravenous iron therapy used to treat iron deficiency anemia, especially in CKD patients.
Ferric Carboxymaltose injection is available in Injectable
and strengths such as 50 mg /mL vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ferric Carboxymaltose injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ferric Carboxymaltose injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ferric Carboxymaltose is an advanced intravenous iron supplement used to treat iron deficiency anemia, especially in patients with chronic kidney disease (CKD) or who are intolerant to oral iron. It ensures rapid iron repletion with fewer doses, making it ideal for hospital and dialysis use. In the US, it is marketed as Injectafer, while in the EU, it is known as Ferinject. Widely trusted for its safety and efficacy, Ferric Carboxymaltose is in high demand across Pharma B2B markets. Partner with GMP-certified Ferric Carboxymaltose manufacturers and suppliers to offer this essential therapy worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing